Leadership

Board of Directors

Chairman

Board member since 2024

Education: 

PhD in Neurobiology from Swiss Federal Institute of Technology, Switzerland. Diploma in Biochemistry from University of Zurich, Switzerland.

Other appointments:

CEO of Molecular Health AG, Chairman of the Board at ­Apogenix AG, and Board member at Heidelberg Pharma AG.

Previous experience:

More than 25 years of experience in a number of national and international biotech companies, such as Dievini, Agennix, Sygnis Pharma and Wasag. In these companies Dr. Friedrich von Bohlen acted or held positions such as co-founder and/or CEO or Chairman.

Does not hold any shares in Orexo.1

Independent in relation to Orexo, its management and the company’s largest shareholder

Board member

Board member since 2023.

Education:

Management Studies at University of Reading and a BSc. in Molecular Biology from University of Portmouth, UK.

Other appointments: 

Senior Vice President, Head of Global Regulatory Affairs & Global Safety, ­Medical Writing and R&D Quality, at Novo ­Nordisk A/S.

Previous experience:

Over 25 years of experience in the pharmaceutical industry, with expertise in the development of biologics, vaccines and small molecule drugs. Evers has held senior positions in drug development at Novo Nordisk since 2013, prior to which he was VP Worldwide Safety & Regulatory at Pfizer Inc. and VP and Head of Global Regulatory Affairs for Europe, Middle East & Africa at Wyeth Pharmaceuticals.

 

Does not hold any shares in Orexo.1

Independent in relation to Orexo and its management, but dependent in relation to the company’s largest shareholders.

Board member

Board member since 2002.

Education: 

M.Sc. in Engineering.

Other appointments:

Partner of HealthCap since 1997, Board member of HealthCap AB, Doctrin AB, Elsa Science AB, GET.ON Institut für Online Gesundheitstrainings GmbH, and The Swedish Association of Exchange-listed companies.

Previous experience:

Ten years in investment banking.

 

Holds 34,144 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.

Board member

Board member since 2022.

Education: 

BSc. in Business Administration and Economics from Stockholm University.

Other appointments:

Board member of CoinShares International Ltd, Bonesupport AB, 4C Group AB and Starbreeze AB.

Previous experience:

Board member of Adventure Box Technology AB and Technopolis Plc. SVP Corporate Control at Veoneer Inc, CFO at Cherry AB, interim CFO/Head of Finance at Serneke Group, Head of Corporate Control at Spotify and Partner/Head of the US Capital Markets group in Sweden at PwC.

 

Holds 7,927 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.

Board member

Board member since 2019

Education: 

MBA., B.Sc. Pharmacy

Other appointments:

Board member of Alter Pharma Group.

Previous experience:

Chief Executive Officer and Board member of Impax Laboratories, Inc., President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan), President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corporation, Inc.

 

Holds 14,000 shares.1

Independent in relation to Orexo, its management and the company’s largest shareholders.

 

 

Management

President and CEO

President and CEO since 2013, employed since 2011.

Education: 

BSc. in Economics and Business law, and MSc. in International Business from Copenhagen Business School. Graduate studies in law at University of Glasgow and Finance at Stockholm School of Economics.

Other appointments:

Member of the Board of Moberg Pharma AB and Gesynta Pharma AB.

Previous experience:

Senior management positions at Pfizer Inc. focusing on commercialization in Europe and Managing Director at Pfizer AB. Prior to that, management consultant at Boston Consulting Group, leading several projects within M&A, commercial transformation, and turn-arounds. Board positions in the life science industry both corporate and industry associations.

 

Holds 179,278  shares and stock options/share awards entitling to 701,405 shares.1

EVP and Chief Financial Officer

EVP and Chief Financial Officer since 2022

Education: 

BSc. and MSc. majoring in Accounting and Finance at the Stockholm School of Economics, Sweden, and International Business at the University of Michigan – Stephen M. Ross School of Business, US.

Previous experience:

CFO Vivesto AB, CFO and Deputy CEO Karolinska Development AB, CFO Bactiguard AB, Director Business Development at Aleris AB, Investment Manager at Litorina Kapital and positions within Corporate Finance at Lazard and SEB Enskilda.

 

Holds 26,190 shares and stock options/share awards entitling to 361,906 shares.1

CEO Orexo US Inc.

President of Orexo US Inc. since 2013

Education: 

R.Ph.

Other appointments:

Member of the American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations. Co-chair, SDHB PheoPara Coalition.

Previous experience:

Extensive experience from leading positions within commercialization at the multinational pharmaceutical companies SanofiAventis, SheringPlough, Berlex, Pharmacia and Archimedes Pharmaceuticals.

 

Holds 17,585 shares and stock options/share awards entitling to 363,124 shares.1

Chief Medical Officer

Chief Medical Officer since 2022

Education: 

MBA in Healthcare Management from University of Massachusetts, US, PhD in Medicine from Thomas Jefferson University, USA and AB in biology from Harvard University.

Previous experience:

Extensive experience in medical affairs, health economics and outcomes research and clinical development in several senior positions in the pharmaceutical industry. Most recently as VP and Head of Medical Affairs at Biohaven Pharmaceuticals. Prior to that, over a decade of experience in clinical practice, academia, and hospital administration as a board-certified psychiatrist.

 

Does not hold any shares in Orexo. Owns stock options/share awards entitling to 143,915 shares.1

SVP and Head of R&D

SVP and Head of R&D since 2019, employed since 2007.

Education:

MSc. in Chemical Engineering and PhD. in Medicinal Chemistry, Uppsala University, Sweden.

Previous experience:

Head of Pharmaceutical Development & IP at Orexo AB since 2016. Prior to that, extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB.

 

Holds 20,280 shares and stock options/share awards entitling to 285,764 shares.1

SVP and Head of Operations

SVP and Head of Operations since 2019, employed since 2006.

Education:

MSc in Chemical Engineering, Uppsala University, Sweden.

Previous experience:

Head of Supply Chain & Planning at Orexo since 2014. Prior to that, senior positions in global pharmaceutical manufacturing, and supply chain at Orexo. Key positions in drug development and project management at AstraZeneca.

 

Holds 14,390 shares stock options/share awards entitling to 257,877 shares.1

Board committees

View the Board Committees here:

Board Committees

1 As of December 31, 2024